Abstract: The present invention provides compositions and methods for the treatment of /??s-expressing tumors using at least one DAC inhibitor (e.g., romidepsin).

Abstract: The present invention provides compositions and methods for the treatment of cell proliferative disorders using at least one DAC inhibitor and gemcitabine.

Abstract: The invention provides methods for increasing the level of human fetal hemoglobin in a subject or cell in need thereof. The methods can be used with subjects suffering from a ?-chain hemoglobinopathy including thalassemia (e.g., ?-thalassemia) or sickle cell anemia.

Abstract: The present invention provides compositions and methods for the treatment of cell proliferative disorders using at least one DAC inhibitor and gemcitabine.

Abstract: The invention provides therapy for treating cancers, such as Bcl-2+ cancers, and Bcl-XL? cancers, and other neoplasms, using romidepsin. The invention provides, inter alia, methods of treating lymphomas, e.g., lymphomas characterized by one or more of Bcl-2 expression, lack of overexpression of Bcl-XL, lack of overexpression of P-glycoprotein, with romidepsin. In some embodiments, the lymphoma is a cutaneous T cell lymphoma. In some embodiments, the lymphoma is a peripheral T cell lymphoma. Romidepsin can be administered a dosages ranging from 0.5 mg/m2 to approximately 28 mg/m2 (e.g., from 1 mg/m2 to 15 mg/m2, from 4 mg/m2 to 15 mg/m2, from 8 mg/m2 to 14 mg/m2, or from 4 mg/m2 to approximately 10 mg/m2). Romidepsin can be administered with a second agent, such as a cytotoxic agent, a steroidal agent, a proteasome inhibitor, or a kinase inhibitor.

Abstract: The present invention relates to HDAC inhibitor derivatives, particularly derivatives of the free thiol of metabolites of the HDAC inhibitor FK228, pharmaceutical compositions thereof, and to methods of using such derivatives and pharmaceutical compositions thereof in the treatment of diseases associated with HDAC, in particular, tumor or cell proliferation diseases.

Abstract: The invention provides methods for increasing the level of human fetal hemoglobin in a subject or cell in need thereof. The methods can be used with subjects suffering from a ?-chain hemoglobinopathy including thalassemia (e.g., ?-thalassemia) or sickle cell anemia.

Abstract: The present invention provides compositions and methods for the treatment of cell proliferative disorders using at least one DAC inhibitor and gemcitabine.

Abstract: The present invention provides compositions and methods for the treatment of /??s-expressing tumors using at least one DAC inhibitor (e.g., romidepsin).

Abstract: The invention provides a combination therapy for treating cancer and other neoplasms including romidepsin and a proteasome inhibitor. When administered together, romidepsin and a proteasome inhibitor (e.g., bortezomib) interact synergistically to selectively kill malignant cells at low (nanomolar) concentrations. The effect is particularly pronounced in malignant hematological cells (e.g., leukemia, lymphoma, multiple myeloma). The combination has also been found useful in treating bortezomib-resistant cancers and steroid-resistant cancers. The invention provides methods of killing malignant cells in vitro and in vivo. Pharmaceutical compositions, preparations, and kits including romidepsin and a proteasome inhibitor are also provided.

Abstract: The present invention relates to HDAC inhibitor derivatives, particularly derivatives of the free thiol of metabolites of the HDAC inhibitor FK228, pharmaceutical compositions thereof, and to methods of using such derivatives and pharmaceutical compositions thereof in the treatment of diseases associated with HDAC, in particular, tumor or cell proliferation diseases.

Abstract: An expression construct is disclosed which is useful for delivering an exogenous polypeptide (e.g. a growth hormone such as somatotropin) to a host. In one application of the invention, the expression construct is introduced into a non-host recombinant cell encapsulated in a semi-permeable membrane for implantation into the host. The semi-permeable membrane inhibits immune surveillance and cell rejection events so that non-host, highly expressing, recombinant cells can be used.

Abstract: An expression construct is disclosed which is useful for delivering mature somatotropin to a host. Mature somatotropin is operably linked to an insulin secretory signal. Host cells comprising the expression cassette are cultured under conditions enabling the expression and secretion of somatotropin.